

25 May 2026

Subject: Site recruitment activity during 2025

Study Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

Protocol Number: IM0271015

EudraCT Number: 2023-503699-25

Sponsor: BRISTOL MYERS SQUIBB SRL

Site: IRCCS ISMETT, Palermo

Principal Investigator: Patrizio Vitulo

Hereby, the Sponsor of the study in question, declares that the recruitment activity carried out by the IRCCS ISMETT - Palermo has enrolled in total N° 1 patient, in 2025.

This declaration is released under IRCCS's request to comply with the requirements of the Ministry of Health regarding the evaluation of the activities carried out by the IRCCS - Reporting Current Research 2025 (activities carried out in 2025).

Paola Taglialatela

Associate Director, Global Trial Lead | Global Trial Execution
Global Development Operations (GDO)



Paola Taglialatela

Associate Director, Global Trial
Lead | Global Trial Execution
Global Development Operations
(GDO)

Bristol Myers Squibb
Route de Perreux 1
2017 Boudry
Switzerland

Mobile +41 797551764
Pronouns She/Her/Hers
paola.taglialatela@bms.com